Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Pfizer CEO tests positive for COVID for a second time

Published 09/24/2022, 04:26 PM
Updated 09/24/2022, 05:20 PM
© Reuters. FILE PHOTO: Albert Bourla, CEO of Pfizer attends a discussion at the World Economic Forum (WEF) in Davos, Switzerland May 25, 2022. REUTERS/Arnd Wiegmann
PFE
-
MRNA
-

(Reuters) -Pfizer Inc Chief Executive Officer Albert Bourla said on Saturday he had tested positive for COVID-19.

"I’m feeling well and symptom free," Bourla said in a statement.

Bourla, 60, back in August had contacted COVID and had started a course of the company's oral COVID-19 antiviral treatment, Paxlovid.

Paxlovid is an antiviral medication that is used to treat high-risk people, such as older patients.

Bourla has received four doses of the COVID vaccine developed by Pfizer (NYSE:PFE) and its German partner BioNTech.

The chief executive said he has not yet taken the new bivalent booster.

Developed by Moderna (NASDAQ:MRNA) and the team of Pfizer and BioNTech, the new so-called bivalent shots aim to tackle the BA.5 and BA.4 Omicron subvariants, which make up 84.8% and 1.8%, respectively, of all circulating variants in the United States, based on latest data.

"I’ve not had the new bivalent booster yet, as I was following CDC guidelines to wait three months since my previous COVID case which was back in mid-August," Bourla added.

© Reuters. FILE PHOTO: Albert Bourla, CEO of Pfizer attends a discussion at the World Economic Forum (WEF) in Davos, Switzerland May 25, 2022. REUTERS/Arnd Wiegmann

In August, the FDA authorized Pfizer and Moderna's updated booster shots that target the dominant BA.4 and BA.5 Omicron subvariants.

A federal health agency said this week that over 25 million doses of the so-called bivalent shots had been sent out. That consisted of mostly the Pfizer/BioNTech vaccine, as production of the Moderna vaccine ramps up.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.